Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Recurrent and metastatic nasopharyngeal carcinoma, drawn from the whole corpus: 16 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Median survival in metastatic disease is still a few years.
Nothing recorded yet.
Background: Circulating tumour DNA (ctDNA). Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Which patients with local recurrence should have surgery rather than re-irradiation depends on surgical expertise concentrated in a few centres.
Nothing recorded yet.
Background: Circulating tumour DNA (ctDNA). Also on OnCo: Treatment journeys · Survivorship planner.
Most trials are Chinese and endemic; applicability to non-endemic keratinising disease is uncertain.
EBV-specific cell therapies have not yet reached a positive phase 3.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 14 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
Recurrent/metastatic nasopharyngeal carcinoma, first line with chemotherapy and later lines
A milestone in how this cancer is treated.
Gemcitabine, taxane or capecitabine-based chemotherapy; nivolumab or pembrolizumab if no prior PD-1 antibody; trials of antibody-drug conjugates (MRG003, BL-B01D1, YL201) and EBV-specific T cells.
Gemcitabine and cisplatin with a PD-1 antibody (toripalimab, JUPITER-02; camrelizumab, CAPTAIN-1st; tislelizumab; penpulimab), then PD-1 maintenance; locoregional radiotherapy to the primary in patients with a good response.